Recruiting

Testing a new antibody injection for severe skin inflammation in teenagers

Plain-English translation of NCT06765005 on ClinicalTrials.gov ↗ · Source last updated January 2025 · Translation generated June 2026 · How we translate trials

Read our Atopic Dermatitis research guide →

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing , a new humanized monoclonal antibody medication, to see if it can safely and effectively treat moderate to severe atopic dermatitis (eczema) in teenagers. The study will track how well the medication works, how your body processes it, and what side effects, if any, you might experience. This is an early-stage trial, meaning we're still learning the basics about this treatment in young people.

Many teenagers with severe eczema don't get enough relief from topical creams and lotions, or they experience serious side effects from those treatments. This trial aims to provide a new option — an injectable antibody that may work differently to calm the immune system and reduce severe skin inflammation.

Do you qualify?

You likely qualify if…

you are between 12 and 18 years old and weigh at least 30 kg (about 66 pounds)
you have been diagnosed with moderate to severe atopic dermatitis (eczema) for at least 6 months
your eczema affects at least 10% of your body and causes significant symptoms despite current treatments
you have tried strong topical corticosteroid creams or other standard treatments for at least 2–4 weeks without adequate improvement, or you cannot safely use topical treatments
you are willing to use effective birth control throughout the study and for 6 months after your final injection (if you are or could become sexually active)
you and your parent or guardian can read, understand, and sign an informed consent form

You likely don't qualify if…

you are pregnant, breastfeeding, or planning to become pregnant during the study
you have had a severe allergic reaction to any monoclonal antibody or similar biologic medication in the past
you have an active infection or serious illness that would make it unsafe to participate
you are currently taking certain other biologic medications for eczema or immune conditions without stopping them first

What participation looks like

You will visit the research clinic regularly for check-ups and receive injections under the skin every two weeks. At each visit, the research team will examine your skin, ask how you're feeling, and possibly take blood samples to monitor your health and how your body is processing the medication. The trial involves careful tracking over several months to ensure the treatment is safe and to see whether your eczema improves.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(1 site)

China

Hangzhou First People's Hospital;, Hangzhou, Zhejiang